Enterprise League logo

Service

STEM-MYO Program

BIOTECHNOLOGY

byImmunis, Inc.

United States (US)

ABOUT THE SERVICE

A Phase 1/2a clinical trial testing the safety, tolerability, and preliminary efficacy of IMM01-STEM in elderly individuals with age-related muscle atrophy associated with knee osteoarthritis.

Information is owner-confirmed

Last updated 1 month ago

Price range
N/A

Other products/services from Immunis, Inc.